ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates

 

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Items In This Category

 TitleCreatedDownload
application/pdfDrug safety Update MHRA Sept-2021-DSU-PDF.pdf (208KB)15/09/2021Download
 Topical corticosteroids: information on the risk of topical steroid withdrawal reactions. COVID-19 vaccines and medicines: updates for August 2021.  
application/pdfDrug Safety Update MHRA August -2021-DSU-PDF.pdf (179KB)31/08/2021Download
  
application/pdfDrug Safety Update MHRA July-2021-DSU-PDF.pdf (280KB)08/07/2021Download
 Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years . Herbal and homeopathic medicines: reminder to be vigilant for suspected adverse reactions... 
application/pdfDrug Safety Update MHRA June-2021-DSU-PDF.pdf (226KB)17/06/2021Download
 CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases. Atezolizumab (Tecentriq▼) and other immune-stimulatory... 
application/pdfDrug Safety Update MHRA May-2021-DSU-PDF.pdf (192KB)19/05/2021Download
 Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products. COVID-19 vaccines: updates for May 2021.  
application/pdfDrug Safety Update MHRA April 2021.pdf (188KB)28/04/2021Download
 Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect when mixed, leading to an increased risk of aspiration. COVID-19 vaccines: updates for April 2021.  
application/pdfDrug Safety Update MHRA March-2021-DSU-PDF.pdf (221KB)25/03/2021Download
 Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML) :COVID-19 vaccines and medicines: updates for March 2021 : 
application/pdfDrug Safety update MHRA February-2021-DSU-PDF_final.pdf (300KB)23/02/2021Download
 Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury. injury page 2 Pregabalin (Lyrica): reports of severe respiratory depression. Alkindi (hydrocortisone... 
application/pdfDrug Safety Update MHRA January 2021 PDF.pdf (361KB)07/01/2021Download
  Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review page: COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice. Dimethyl fumarate... 
application/pdfDrug Safety Update MHRA December 2020-DSU-PDF-1712.pdf (263KB)18/12/2020Download
 Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk: Erythromycin: caution required due to cardiac risks (QT... 
application/pdfDrug Safety Update MHRA November 2020 PDF.pdf (308KB)16/11/2020Download
 Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy. Pirfenidone (Esbriet): risk of serious liver injury, and updated advice on liver function testing . Ferric... 
application/pdfDrug Safety Update MHRA October 2020.pdf (295KB)22/10/2020Download
 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity. Flucytosine (Ancotil): new... 
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9]